Rapid Increase in Lymphogranuloma Venereum among HIV-Negative Men Who Have Sex with Men, England, 2019 by Prochazka, Mateo et al.
Lymphogranuloma venereum (LGV) is an inva-sive form of Chlamydia trachomatis infection. In 
high-income countries, LGV is concentrated among 
gay, bisexual, and other men who have sex with men 
(MSM) (1). Although LGM was initially character-
ized as affecting predominantly MSM living with 
HIV who have symptomatic proctitis (2,3), recent evi-
dence suggests considerable underestimation of the 
actual extent of LGV among MSM in Europe because 
of insuffi cient testing of asymptomatic persons (4). 
Changes to UK guidelines (5) and testing practices 
of several large London clinics have led to expanded 
testing in MSM regardless of HIV status, leading to 
increased diagnoses among HIV-negative MSM and 
those without symptoms of proctitis (6–9). Expanded 
testing may have precipitated a decline in incidence 
during 2016–2018 (9); however, 2019 saw the highest 
number of LGV diagnoses reported in England since 
routine testing began in 2004, and test positivity in-
creased from 8.2% in 2018 to 9.0% in 2019 (10). In this 
study, we investigated the changing epidemiology of 
LGV among MSM in England during 2015–2019 and 
risk factors associated with recent cases.
The Study
We conducted a retrospective analysis of adult 
(>16 years of age) MSM in England who visited 
sexual health service (SHS) sites during January 1, 
2015–December 31, 2019. We obtained data from 
the Genitourinary Medicine Clinic Activity Data-
set Sexually Transmitted Infection (STI) Surveil-
lance System, which has recorded LGV diagnoses, 
obtained through multiplex reverse transcription 
PCR (4), since 2011. We included all SHS site visits 
by men who self-reported as MSM in England dur-
ing 2015–2019. We cleaned and deduplicated data 
according to a routine practice described previously 
(11). We described the number of annual LGV diag-
noses during 2015–2019 by age group, race (White 
[e.g., White British, White Irish, or White other back-
ground] and non-White), place of residence (London 
or rest of England), region of birth (United Kingdom, 
Europe, Asia, Oceania, Latin America and the Carib-
bean [LAC], North America, and Africa), history of 
a bacterial STI in the previous year (defi ned as hav-
ing a recorded diagnoses of chlamydia, gonorrhea, 
or syphilis in the 365 days before attendance), and 
HIV status at time of LGV diagnosis. We used quar-
terly data on LGV diagnoses stratifi ed by HIV sta-
tus to examine changes over time in the proportion 
of diagnoses that were made among MSM who are 
HIV-negative or with unknown HIV status. We used 
generalized linear models with logarithmic function, 
Poisson distribution, and robust variances to identify 
the changes in risk for LGV in 2019 by quarter. We in-
cluded covariates in the model if they showed strong 
association with an LGV diagnosis in the bivariate 
analyses (p<0.05). We adjusted the fi nal model for 
HIV status, history of a previous bacterial STI, region 
of birth, and age group. We performed all data analy-
ses using Stata 15.1 (https://www.stata.com).
Public Health England collects pseudonymized, 
electronic data on all STI tests and diagnoses from 
all commissioned SHS sites in England (11). Public 
Rapid Increase in 
Lymphogranuloma Venereum 
among HIV-Negative Men Who 
Have Sex with Men, England, 2019
Mateo Prochazka, Hannah Charles, Hester Allen, Michelle Cole, Gwenda Hughes, Katy Sinka
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 10, October 2021 2695
Author affi  liation: Public Health England, London, UK
DOI: https://doi.org/10.3201/eid2710.210309
Incidence of lymphogranuloma venereum increased in 
England during 2018–2019, after a period of decline. Our 
retrospective analysis of national surveillance data iden-
tifi ed a rapid increase in diagnoses among HIV-negative 
men who have sex with men. These fi ndings indicate 
a need for sustained surveillance and targeted public 
health action.
DISPATCHES
Health England has approval to handle data obtained 
by the Genitourinary Medicine Clinic Activity Data-
set STI Surveillance System under Regulation 3 of the 
Health Service (Control of Patient Information) Regu-
lations 2002 (https://www.gov.uk/government/
publications/hiv-and-sti-data-sharing-policy).
Of 2,116,345 SHS visits by MSM during 2015–
2019, we identified 3,461 diagnoses of LGV (Table 1). 
The highest number of LGV diagnoses was recorded 
in 2019 (n = 1,018); this increase was mainly attributed 
to increases in diagnoses in the third and fourth quar-
ter of the year (Figure 1). The proportion of diagnoses 
among MSM who are HIV-negative or with unknown 
HIV status increased from 31.4% in 2015 to 58.4% in 
2019 (Table 1). In 2019, most LGV diagnoses in MSM 
were among White MSM (72.7%) and MSM residing 
in London (79.1%). A total of 614 (60.3%) LGV diag-
noses in 2019 were made among those who had a bac-
terial STI diagnosis in the previous year (Table 1).
Our regression analyses included 526,102 visits 
and 1,018 LGV diagnoses among MSM in England 
in 2019 (Table 2). Compared with quarter 1 of 2019, 
the risk for having LGV diagnosed was 73% higher 
in quarter 3 and 66% higher in quarter 4. Living with 
HIV, residing in London, and having a previous 
bacterial STI were strongly associated with an LGV di-
agnosis in the crude and adjusted models (Table 2). Be-
ing born in LAC or in Europe outside of the UK were 
also associated with increased risk for LGV (Figure 2).
Conclusions
We show that a rapid increase occurred in LGV diag-
noses in England in 2019, particularly affecting MSM 
who are HIV-negative or with unknown HIV status, 
such that nearly 60% of all LGV diagnoses are now 
in this group. This trend represents a major shift in 
the epidemiology of LGV; infection was previously 
associated with MSM living with HIV (2). However, 
having LGV diagnosed continues to be associated 
with living with HIV, as well as having a previous 
STI diagnosis, residing in London, and being born in 
LAC or Europe outside the United Kingdom.
An earlier decline in LGV diagnoses (9) has been 
attributed to revisions to LGV testing guidelines that 
led to expanded testing (5,12). However, because no 
revisions have been made since 2015, changes to test-
ing practice are unlikely to explain the recent increase, 
which is concurrent with increases in test positivity 
(10). Of note, use of HIV preexposure prophylaxis 
(PrEP) in England may have contributed to increased 
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Table 1. Characteristics of men who have sex with men who had lymphogranuloma venereum diagnosed, England, 2015–2019* 
Characteristic 
No. (%) patients 
2015 2016 2017 2018 2019 
Total no. patients 663 620 505 655 1,018 
Age group, y      
 16–24 45 (6.8) 31 (5.0) 40 (7.9) 27 (4.1) 81 (8.0) 
 25–34 250 (37.7) 234 (37.7) 166 (32.9) 243 (37.1) 377 (37.0) 
 35–44 229 (34.5) 208 (33.6) 141 (27.9) 219 (33.4) 301 (29.6) 
 45–54 103 (15.5) 115 (18.6) 124 (24.6) 122 (18.6) 180 (17.7) 
 55–64 26 (3.9) 24 (3.9) 25 (5.0) 32 (4.9) 68 (6.7) 
 >65 4 (0.6) 5 (0.8) 5 (1.0) 11 (1.7) 7 (0.7) 
 Unknown 6 (0.9) 3 (0.5) 4 (0.8) 1 (0.2) 4 (0.4) 
Residence      
 London 512 (77.2) 469 (75.7) 362 (71.7) 507 (77.4) 806 (79.1) 
 Rest of England 151 (22.8) 151 (24.4) 143 (28.3) 148 (22.6) 212 (20.8) 
Race      
 White 499 (75.3) 479 (77.3) 383 (75.8) 485 (74.0) 740 (72.7) 
 Non-White 124 (18.7) 121 (19.5) 99 (19.6) 125 (19.1) 208 (20.4) 
 Unknown 40 (6.0) 20 (3.2) 23 (4.6) 45 (6.9) 70 (6.9) 
Region of birth      
 United Kingdom 333 (50.2) 317 (51.1) 248 (49.1) 300 (45.8) 443 (43.5) 
 Europe 159 (24.0) 139 (22.4) 112 (22.2) 172 (26.3) 256 (25.2) 
 Asia 38 (5.7) 33 (5.3) 25 (5.0) 38 (5.8) 50 (4.9) 
 Oceania 10 (1.5) 13 (2.1) 7 (1.4) 18 (2.8) 28 (2.8) 
 Latin America and Caribbean 51 (7.7) 41 (6.6) 45 (8.9) 44 (6.7) 111 (10.9) 
 Northern America 9 (1.4) 7 (1.1) 22 (4.4) 18 (2.8) 18 (1.8) 
 Africa 14 (2.1) 23 (3.7) 13 (2.6) 25 (3.8) 31 (3.1) 
 Unknown 49 (7.4) 47 (7.6) 33 (6.5) 40 (6.1) 81 (8.0) 
Bacterial STI in previous year      
 Yes 310 (46.8) 276 (44.5) 217 (43.0) 356 (54.4) 614 (60.3) 
 No 353 (53.2) 344 (55.5) 288 (57.0) 299 (45.7) 404 (39.7) 
HIV status      
 Living with HIV 455 (68.6) 420 (67.7) 299 (59.2) 302 (46.1) 424 (41.7) 
 Negative or unknown status 208 (31.4) 200 (32.7) 206 (40.8) 353 (53.9) 594 (58.4) 
*STI, sexually transmitted infection. 
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testing for C. trachomatis and subsequent detection of 
LGV. Increased access to HIV prevention, including 
PrEP, in HIV-negative MSM engaging in high-risk 
sexual activities may have facilitated the change in 
the epidemiology of LGV and led to the observed 
increase in incidence among this group (13); the 
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Figure 1. Annual and quarterly number of lymphogranuloma venereum diagnoses among men who have sex with men, by HIV status, 
England, 2015–2019. 
 
Table 2. Crude and adjusted incidence rate ratios for lymphogranuloma venereum among men who have sex with men, England, 2019* 
Characteristic Crude incidence rate ratio (95% CI) Adjusted† incidence rate ratio (95% CI) 
Year   
 Quarter 1 Referent Referent 
 Quarter 2 1.10 (0.90–1.35) 1.13 (0.92–1.40) 
 Quarter 3 1.68 (1.40–2.02) 1.73 (1.43–2.10) 
 Quarter 4 1.49 (1.24–1.80) 1.66 (1.36–2.01) 
HIV   
 Negative or unknown status Referent Referent 
 Living with HIV 2.55 (2.26–2.90) 2.23 (1.93–2.57) 
Bacterial STI in previous year   
 No Referent Referent 
 Yes 4.01 (3.54–4.55) 3.17 (2.77–3.63) 
Residence   
 Rest of England Referent Referent 
 London 4.28 (3.68–4.98) 3.62 (3.06–4.28) 
Region of birth   
 United Kingdom Referent Referent 
 Europe 2.42 (2.07–2.82) 1.30 (1.10–1.53) 
 Asia 1.27 (0.95–1.70) 0.82 (0.61–1.10) 
 Oceania 2.96 (2.02–4.33) 1.44 (0.98–2.12) 
 Latin America and Caribbean 3.78 (3.07–4.65) 1.59 (1.27–1.98) 
 North America 1.89 (1.18–3.02) 1.09 (0.68–1.75) 
 Africa 1.60 (1.11–2.30) 0.90 (0.62–1.30) 
Age group, y   
 16–24 Referent Referent 
 25–34 2.16 (1.70–2.75) 1.40 (1.09–1.81) 
 35–44 2.67 (2.09–3.42) 1.49 (1.14–1.94) 
 45–54 2.48 (1.91–3.22) 1.47 (1.10–1.96) 
 55–64 2.00 (1.45–2.76) 1.60 (1.13–2.26) 
 >65 0.58 (0.27–1.25) 0.55 (0.23–1.28) 
*Ratios determined by using generalized linear models using a logarithmic linking function and Poisson distribution with robust variances.  
†Adjusted for all the covariates shown in the table. 
 
DISPATCHES
association with previous STI diagnosis further sup-
ports this hypothesis. Further investigation will be 
needed to understand the impact of HIV prevention 
on transmission of bacterial STIs. However, the in-
creasing proportion of LGV diagnoses among HIV-
negative MSM during 2017–2019 is in line with re-
ports from other countries in Europe (6,8,14,15).
The first limitation of this study is that unmea-
sured behavioral covariates (e.g., number of part-
ners, PrEP use, drug use, group sex, and venue-
based activities) were not available. Inclusion of 
behavioral covariates in routine STI surveillance 
in England is underway and will be examined in 
future iterations of these analyses. Second, the risk 
among some groups, such as those not born in the 
United Kingdom, could be overestimated because 
of differing patterns of healthcare access and bar-
riers to access.
In summary, we report a steep increase in the 
number of LGV diagnoses identified in SHS sites af-
ter a period of decline, which indicates the need for 
sustained surveillance and public health action. Our 
findings indicate that the epidemiology of LGV has 
changed, and an increased number of diagnoses are 
occurring among MSM who are HIV-negative or 
with unknown HIV status, highlighting the need to 
integrate health promotion and increase LGV test-
ing within HIV prevention delivery. In addition, in-
creased LGV risk among MSM born in LAC and in 
countries in Europe that are outside the United King-
dom indicates the need for increased accessibility of 
health promotion materials and wider engagement 
with these communities.
About the Author
Dr. Prochazka is a medical doctor and epidemiologist 
focused on control of infectious diseases. He is a  
consultant epidemiology scientist supporting STI and 
COVID-19 surveillance at Public Health England.
References
  1. Childs T, Simms I, Alexander S, Eastick K, Hughes G,  
Field N. Rapid increase in lymphogranuloma venereum in 
men who have sex with men, United Kingdom, 2003  
to September 2015. Euro Surveill. 2015;20:30076.  
https://doi.org/10.2807/1560-7917.ES.2015.20.48.30076
  2. Hughes G, Alexander S, Simms I, Conti S, Ward H,  
Powers C, et al.; LGV Incident Group. Lymphogranuloma 
venereum diagnoses among men who have sex with  
men in the U.K.: interpreting a cross-sectional study  
using an epidemic phase-specific framework. Sex Transm 
Infect. 2013;89:542–7. https://doi.org/10.1136/ 
sextrans-2013-051051
  3. Saxon C, Hughes G, Ison C; UK LGV Case-Finding Group. 
Asymptomatic lymphogranuloma venereum in men who 
have sex with men, United Kingdom. Emerg Infect Dis. 
2016;22:112–6. https://doi.org/10.3201/EID2201.141867
  4. Cole MJ, Field N, Pitt R, Amato-Gauci AJ, Begovac J,  
French PD, et al. Substantial underdiagnosis of  
lymphogranuloma venereum in men who have sex with  
men in Europe: preliminary findings from a multicentre  
surveillance pilot. Sex Transm Infect. 2020;96:137–42. 
https://doi.org/10.1136/sextrans-2019-053972
  5. Nwokolo NC, Dragovic B, Patel S, Tong CY, Barker G, 
Radcliffe K. 2015 UK national guideline for the manage-
ment of infection with Chlamydia trachomatis. Int J STD AIDS. 
2016;27:251–67. https://doi.org/10.1177/0956462415615443
  6. van Aar F, Kroone MM, de Vries HJ, Götz HM,  
van Benthem BH. Increasing trends of lymphogranuloma 
venereum among HIV-negative and asymptomatic men  
who have sex with men, the Netherlands, 2011 to 2017.  
Euro Surveill. 2020;25. https://doi.org/10.2807/ 
1560-7917.ES.2020.25.14.1900377
2698 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 10, October 2021
Figure 2. Adjusted incidence 
rate ratios for lymphogranuloma 
venereum among men who 
have sex with men, England, 
2019. Diamonds indicate effect 
estimates (incidence rate ratio); 
error bars indicate 95% CIs for 
those estimates. LAC, Latin 
America and the Caribbean; Q, 
quarter; STI, sexually transmitted 
infection; UK, United Kingdom.
Increase in Lymphogranuloma Venereum, England
  7. Peuchant O, Touati A, Laurier-Nadalié C, Hénin N, 
Cazanave C, Bébéar C, et al. Prevalence of lymphogranuloma 
venereum among anorectal Chlamydia trachomatis-positive 
MSM using pre-exposure prophylaxis for HIV. Sex Transm 
Infect. 2020;96:615–7. https://doi.org/10.1136/
sextrans-2019-054346
  8. De Baetselier I, Tsoumanis A, Verbrugge R, De Deken B, 
Smet H, Abdellati S, et al. Lymphogranuloma venereum is 
on the rise in Belgium among HIV negative men who have 
sex with men: surveillance data from 2011 until the 
end of June 2017. BMC Infect Dis. 2018;18:689. 
https://doi.org/10.1186/s12879-018-3600-0
  9. Allen H, Pitt R, Bardsley M, Smolarchuk C, Sullivan A, 
Mohammed H, et al. Investigating the decline in 
lymphogranuloma venereum diagnoses in men who have 
sex with men in the United Kingdom since 2016: an 
analysis of surveillance data. Sex Health. 2020;17:344–51. 
https://doi.org/10.1071/SH20001
10. Charles H, Prochazka M, Sinka K. Trends of 
lymphogranuloma venereum in England: 2019. Health 




11. Public Health England. GUMCAD STI Surveillance System: 
data specifi cation and technical guidance. 2020 Apr [cited 




12. White J, O’Farrell N, Daniels D; British Association for 
Sexual Health and HIV. 2013 UK national guideline
for the management of lymphogranuloma venereum. Int J 
STD AIDS. 2013;24:593–601. https://doi.org/10.1177/
0956462413482811
13. Gafos M, Horne R, Nutland W, Bell G, Rae C, Wayal S, 
et al. The context of sexual risk behaviour among men who 
have sex with men seeking PrEP, and the impact of PrEP on 
sexual behaviour. AIDS Behav. 2019;23:1708–20. 
https://doi.org/10.1007/s10461-018-2300-5
14. Marangoni A, Foschi C, Tartari F, Gaspari V, Re MC. 
Lymphogranuloma venereum genovariants in men having 
sex with men in Italy. Sex Transm Infect. Sex Transm Infect. 
2020 Oct 26 [Epub ahead of print]. https://doi.org/10.1136/
sextrans-2020-054700
15. Martínez-García L, Rodríguez-Domínguez M, Lejarraga C, 
Rodríguez-Jiménez MC, González-Alba JM, Puerta T, et al. 
The silent epidemic of lymphogranuloma venereum inside 
the COVID-19 pandemic in Madrid, Spain, March 2020 to 
February 2021. Euro Surveill. 2021;26:2100422. 
https://doi.org/10.2807/1560-7917.ES.2021.26.18.2100422
Address for corresponding: Hannah Charles, Public Health 
England, 61 Colindale Ave, London, NW9 5EQ, UK; email 
hannah.charles@phe.gov.uk





Neospora caninum [ne-os′ pə-rə ca-nin′ um]
From the neo- (Latin, “new”) + spora (Greek, “seed”)
and canis (Latin, “dog”), Neospora caninum is a sporozoan 
parasite that was fi rst described in 1984. It is a major pathogen 
of cattle and dogs but can also infect horses, goats, sheep, and 
deer. Antibodies to N. caninum have been found in humans, 
predominantly in those with HIV infection, although the role 
of this parasite in causing or exacerbating illness is unclear.
Sources: 
1. Bjerkås I, Mohn SF, Presthus J. Unidentifi ed cyst-forming sporozoon causing 
    encephalomyelitis and myositis in dogs. Z Parasitenkd. 1984;70:271–4. 
    http://dx.doi.org/10.1007/BF00942230
2. Dubey JP. Review of Neospora caninum and neosporosis in animals. Korean J    
    Parasitol. 2003; 41:1–16. http://dx.doi.org/10.3347/kjp.2003.41.1.1
3. Lobato J, Silva DA, Mineo TW, Amaral JD, Segundo GR, Costa-Cruz JM, et al.   
    Detection of immunoglobulin G antibodies to Neospora caninum in humans:     
    high seropositivity rates in patients who are infected by human 
    immunodefi ciency virus or have neurological disorders. Clin Vaccine Immunol.    
    2006;13:84–9. http://dx.doi.org/10.1128/CVI.13.1.84-89.2006
